Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05738642Not ApplicableCompleted

Efficacy and Safety of Early Use PCC in Severe Trauma

Role: collaborator

NCT07203248Not Yet Recruiting

Chinese Real-world Study of Treatment of Vestibular Migraine

Role: collaborator

NCT07078500Phase 2Recruiting

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT04939922Recruiting

China Headache and Vertigo Registry Study

Role: collaborator

NCT07022223Phase 2Recruiting

Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

Role: collaborator

NCT06444425Enrolling By Invitation

Artificial Intelligence in Detecting Cardiac Function

Role: collaborator

NCT03520439Phase 2Completed

Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

Role: collaborator

All 7 trials loaded